Because of the risks associated with the ErbB2–ErbB3 complex inhibition, close patient monitoring and patient categorization have to be taken into account when considering an anti-ErbB2–ErbB3 therapy in IPF. The gene discussed is ERBB3; the disease is idiopathic pulmonary fibrosis.